Cibc World Market Inc. reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 37.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,862 shares of the biopharmaceutical company’s stock after selling 5,871 shares during the quarter. Cibc World Market Inc.’s holdings in Regeneron Pharmaceuticals were worth $7,612,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently added to or reduced their stakes in the business. TD Private Client Wealth LLC increased its stake in Regeneron Pharmaceuticals by 9.7% in the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 15 shares during the last quarter. CYBER HORNET ETFs LLC grew its position in Regeneron Pharmaceuticals by 6.0% during the fourth quarter. CYBER HORNET ETFs LLC now owns 301 shares of the biopharmaceutical company’s stock valued at $232,000 after acquiring an additional 17 shares during the period. Meyer Handelman Co. grew its position in Regeneron Pharmaceuticals by 0.6% during the fourth quarter. Meyer Handelman Co. now owns 2,878 shares of the biopharmaceutical company’s stock valued at $2,221,000 after acquiring an additional 18 shares during the period. Gateway Investment Advisers LLC grew its position in Regeneron Pharmaceuticals by 4.3% during the fourth quarter. Gateway Investment Advisers LLC now owns 464 shares of the biopharmaceutical company’s stock valued at $358,000 after acquiring an additional 19 shares during the period. Finally, MGO One Seven LLC grew its position in Regeneron Pharmaceuticals by 3.3% during the fourth quarter. MGO One Seven LLC now owns 589 shares of the biopharmaceutical company’s stock valued at $455,000 after acquiring an additional 19 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the company. Leerink Partners reissued a “market perform” rating and set a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. Canaccord Genuity Group lowered their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Wells Fargo & Company lowered their price target on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a research report on Monday, May 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $800.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, April 23rd. Finally, Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $792.65.
Insider Buying and Selling
In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.
Regeneron Pharmaceuticals Price Performance
Shares of NASDAQ REGN opened at $635.45 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $485.00 and a 1-year high of $821.11. The business has a 50-day moving average of $706.93 and a 200-day moving average of $742.16. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The company has a market capitalization of $67.18 billion, a price-to-earnings ratio of 15.48, a PEG ratio of 1.40 and a beta of 0.25.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $8.22 earnings per share. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.
Regeneron Pharmaceuticals Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were issued a $0.94 dividend. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.
Regeneron Pharmaceuticals News Summary
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Regeneron expanded its cancer therapy partnership with CytomX Therapeutics, a deal that could generate up to $4 billion in potential milestones and broadens its bispecific oncology pipeline. REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
- Positive Sentiment: The company also reported highly favorable Lynozyfic trial results in light chain amyloidosis, which supports the view that Regeneron’s clinical pipeline may have additional upside. A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
- Positive Sentiment: Regeneron said it will highlight new data from its metabolic disease, ophthalmology and rare disease programs at upcoming ADA and ENDO meetings, giving investors another near-term catalyst to watch. Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
- Neutral Sentiment: Parabilis Medicines, a Regeneron-partnered biotech, is pursuing an IPO to advance zolucatetide into Phase III, which could indirectly reflect on Regeneron’s partner network but does not directly change REGN’s fundamentals. Parabilis eyes $475m IPO to push lead asset into Phase III
- Negative Sentiment: An investor alert from Pomerantz LLP announced an investigation into claims on behalf of Regeneron shareholders, which may create some legal overhang and weigh on sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Articles
- Five stocks we like better than Regeneron Pharmaceuticals
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
